Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

Abbott's heart valve repair device gains US FDA approval

Published 04/02/2024, 09:36 AM
Updated 04/02/2024, 12:15 PM
© Reuters. FILE PHOTO: Abbott Laboratories logo is displayed on a screen at the New York Stock Exchange (NYSE) in New York City, U.S., October 18, 2021. REUTERS/Brendan McDermid/File Photo

By Puyaan Singh

(Reuters) -Abbott Laboratories said on Tuesday the U.S. FDA has approved its heart valve repair device for patients with a potentially fatal heart disease, just months after rival Edwards Lifesciences (NYSE:EW) received the regulator's nod for its device.

The Abbott device, TriClip, aims to treat tricuspid regurgitation (TR), which occurs when the valve separating the right lower chamber of the heart from the right upper does not close properly, causing blood to flow backwards.

The condition typically impacts older individuals with multiple co-morbid conditions such as irregular heartbeat and high blood pressure in the lungs or heart who are at high risk of complications or death due to open-heart surgery.

It is estimated about 1.6 million Americans are affected by the condition, according to government data.

In February, Edwards Lifesciences gained approval for a device that replaces the tricuspid valve. Unlike the Edwards rival, Abbott's device repairs the tricuspid valve by clipping a portion of its flaps to reduce the backflow of blood.

Other options to treat the disease include diuretic drugs, which make patients urinate frequently to prevent a buildup of fluid in the body.

"The key message to remember here is that patients now have options," said Nadim Geloo, Senior Director of Medical Affairs at Abbott's Structural Heart Division.

Geloo said that repairing the valve instead of replacing it is a "very positive treatment path", adding that 98% of the patients who received TriClip had no major adverse events in 30 days.

© Reuters. FILE PHOTO: Abbott Laboratories logo is displayed on a screen at the New York Stock Exchange (NYSE) in New York City, U.S., October 18, 2021. REUTERS/Brendan McDermid/File Photo

Abbott counts TriClip, which is already approved in over 50 countries, in its group of so-called "Fab 5" devices, which are expected to drive sales growth in the next few years.

The device is inserted through the femoral vein in the leg and is then guided and clipped onto the tricuspid valve.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.